Fig. 2From: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort studyDistribution of HCV antiviral regimens by genotypeBack to article page